Posts Tagged Pharmaceutical industry

Keeping pace

PME Pharmaceutical Market Europe June 2017

It was a bumper issue of PME this month as we encompassed creativity, communications and consumerism, and tackled different strands of how pharma looks to reach and engage with its stakeholders.

On an industry level the German pharma market looks set for stable, if not strong, growth over the next four years, but it’s clearly anyone’s guess what will happen over that timeframe to the UK’s political landscape, and how that will in turn affect the industry.

What we can say with certainty is that European regulators aren’t waiting for the region’s politicians to thrash out a deal on the post-Brexit landscape. Instead the last month has seen concrete developments in the future shape of the regulatory environment, with a set of guidance now available, and – more recently – a delay to deciding the new location of the EMA. Read the rest of this entry »

, , ,

Leave a comment

Ready to start?

PME Pharmaceutical Market Europe January 2017

As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.

This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »

, , , ,

Leave a comment

The changing world

pme_pharmaceutical_market_europe_november_2016_lrg

For this month’s issue of PME I spoke with Ipsen’s new chief executive David Meek about his company’s strategy for growth and – appropriately enough, as we sat down at the ESMO meeting in Copenhagen – his hopes for Ipsen’s new cancer drug Cabometyx.

We covered the strategic pillars Ipsen is counting on for success and looked at the strong progress the French firm is making in the US – where for the first year its operations there are its number one affiliate by revenue – and the changes to its primary care business model in China. Read the rest of this entry »

, , , , , , ,

Leave a comment

Med comms, European pharma …. and sandcastles

Sandcastles

July was always going to be busy, but August too seems to have flown by thanks to holidays, holiday cover and some interesting projects that have come my way.

So, there’s just time for a quick July-August post on the last couple of months, which began in traditional style with the 19th Communiqué Awards in London on July 7. You can see the full results here and register interest for next year’s awards here. Read the rest of this entry »

, , , , ,

Leave a comment

Digital disruption, AMNOG and cancer drugs, AZ and its pipeline and more

PME Pharmaceutical Market Europe May 2014Taking aim at digital disruption to pharma the May issue of PME was out this week in both its print and online incarnations.

The issue also featured an exclusive interview with AstraZeneca’s VP of oncology Susan Galbraith who talked about the company’s pipeline prospects – a topic that shortly after the interview was conducted took on added significance. Read the rest of this entry »

, , , , , ,

Leave a comment

PME December/January 2013

PME Pharmaceutical Market EuropeThe latest issue of PME (Pharmaceutical Market Europe) was out this week and it ended up being nicely heavy on ‘digital’.

There was, as usual, my Digital Intelligence column, which this issue covered the EU’s eHealth plans and what they could mean for pharma.

But there was also my first Digital Yearbook, which covered 2012’s headline treads, reviewed the year and looked at what 2013 may offer the industry.

Finally, there was the latest entrant in PMGroup’s 10 Ways … series, which this time offered 10 Ways … to activate digital opinion leaders.

• Read the December/January 2013 issue of PME

, , , ,

Leave a comment

%d bloggers like this: